Post-marketing safety surveillance of lyophilized human rabies vaccine (Vero cell) after exposure

Phase 4, open-label trial of rabies vaccine (Vero cells) in rabies (2 arms), sponsored by Wuhan Jinyintan Hospital. Primary endpoints: Incidence of solicited local and systemic adverse events and reactions within 0–7 days after each vaccination, Incidence of non-solicited adverse events and adverse reactions from first dose to 30 days after completion of vaccination and 5 more. Planned start Dec 2025; status: not yet recruiting.